nach oben

Erschienen in:

01.12.2015 | Original Article

Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1

verfasst von: Kanako Shibata, Yoshinari Yasuda, Ryo Kobayashi, Yuichi Ando, Tomoya Shimokata, Hideki Kamiya, Mutsuharu Hayashi, Shoichi Maruyama, Seiichi Matsuo, Makoto Nakao, Teruo Tsuchiya, Hitomi Teramachi

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Accurate glomerular filtration rate (GFR) evaluation is significant for drug dosing of carboplatin, anticancer drug excreted mainly from kidney. Serum cystatin-C (sCys-C) is a GFR marker with little affected by body muscle mass volume. And GFR equations based on serum creatinine (eGFRcreat) and sCys-C (eGFRcys) were developed; however, accuracy of eGFRcys has not been elucidated fully among patients with cancer. Therefore, we analyzed the performance of GFR equations among patients with cancer whose GFR values were measured by inulin clearance (Cin).

Methods

Study design was a cross-sectional study. Subjects were 41 patients with cancer whose GFR values were measured by Cin for drug dosing studies of carboplatin or S-1 in Nagoya University Hospital from 2007 to 2010 and 29 non-cancer patients. Correlation with Cin and slope of regression line were evaluated in eGFRcreat and eGFRcys. Single and multiple regression analyses were analyzed to identify associating factors with eGFRcreat/Cin or eGFRcys/Cin.

Results

Age, body weight, body mass index (BMI) and sCr were different between cancer patients and non-cancer patients, but sCys-C and Cin were consistent in 2 groups. The slope of the regression line for Cin vs. eGFRcys with zero intercept in cancer patients was 1.10 (95 % CI: 1.02–1.17), which was significantly different from 1.0. In multiple regression analysis revealed that BMI and urinary creatinine excretion were significantly associated with eGFRcreat/Cin, and cancer was only associating factor with eGFRcys/Cin.

Conclusion

eGFRcys should not be used for evaluation of renal function in patients with cancer because it underestimates GFR.

Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–56.PubMed

Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520–8.PubMed

Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol. 2009;20:2305–13.CrossRefPubMed

Itoh Y, Hosogaya S, Ichihara K, et al. Standardization of serum cystatin C immunoassay using calibrator of each assay system, in which assigned values are transerred from ERM-DA471/IFCC. Rinshokagaku. 2012;41:62–71.

Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS. CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.PubMedCentralCrossRefPubMed

Horio M, Imai E, Yasuda Y, Watanabe T. Matsuo S; Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis. 2013;61:197–203.CrossRefPubMed

Grubb A, Horio M, Hansson LO, Björk J, Nyman U, Flodin M, Larsson A, Bökenkamp A, Yasuda Y, Blufpand H, Lindström V, Zegers I, Althaus H, Blirup-Jensen S, Itoh Y, Sjöström P, Nordin G, Christensson A, Klima H, Sunde K, Hjort-Christensen P, Armbruster D, Ferrero C. Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator. Clin Chem. 2014;60:974–86.CrossRefPubMed

Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2011;80:1122–37.CrossRefPubMed

Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N, Vrhovec I. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res. 1997;3:1815–22.PubMed

10.

Kos J, Nielsen HJ, Krašovec M, Christensen IJ, Cimerman N, Stephens RW, Brunner N. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res. 1998;4:1511–6.PubMed

11.

Chew-Harris JS, Florkowski CM, George PM, Endre ZH. Comparative performances of the new chronic kidney disease epidemiology equations incorporating cystatin C for use in cancer patients. Asia Pac J Clin Oncol. 2014. doi:10.1111/ajco.12312.PubMed

12.

Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Performance of GFR equations in Japanese subjects. Clin Exp Nephrol. 2013;17:352–8.CrossRefPubMed

13.

Shimokata T, Ando Y, Yasuda Y, Hamada A, Kawada K, Saito H, Matsuo S, Kondo M, Imaizumi K, Hasegawa Y. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci. 2010;101:2601–5.CrossRefPubMed

14.

Ando Y, Kawada K, Inada M, Morita S, Mitsuma A, Yasuda Y, Hiramatsu M, Fujimoto Y, Fujita K. Pharmacokinetic study of S-1 in patients in whom inulin clearance was measured. Oncology. 2012;83:38–44.CrossRefPubMed

15.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed

16.

Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Umezu M, Otsuki N, Nibu K, Minami H. Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate. Jpn J Clin Oncol. 2013;43:271–7.CrossRefPubMed

17.

Horio M, Imai E, Yasuda Y, Watanabe T, Yokoyama H, Makino H, Matsuo S. Serum albumin, but not glycated albumin was a potent factor affecting the performance of GFR equation based on serum creatinine. Clin Exp Nephrol. 2015;19:284–92.CrossRefPubMed

18.

Nakai K, Kikuchi M, Fujimoto K, Kaneko Y, Omori S, Nakai K, Suwabe A. Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol. 2008;12:132–9.CrossRefPubMed

19.

Demirtaş S, Akan O, Can M, Elmali E, Akan H. Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem. 2006;39:115–8.CrossRefPubMed

20.

Yano M, Hirai K, Naito Z, Yokoyama M, Ishiwata T, Shiraki Y, Inokuchi M, Asano G. Expression of cathepsin B and cystatin C in human breast cancer. Surg Today. 2001;31:385–9.CrossRefPubMed

21.

Cathomas R, Klingbiel D, Geldart TR, Mead GM, Ellis S, Wheater M, Simmonds P, Nagaraj N, von Moos R, Fehr M. Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort. Ann Oncol. 2014;25:1591–7.CrossRefPubMed

22.

Horio M, Imai E, Yasuda Y, Hishida A. Matsuo S; Japanese equation for estimating GFR. Simple sampling strategy for measuring inulin renal clearance. Clin Exp Nephrol. 2009;13:50–4.CrossRefPubMed

Titel: Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1
verfasst von: Kanako Shibata
Yoshinari Yasuda
Ryo Kobayashi
Yuichi Ando
Tomoya Shimokata
Hideki Kamiya
Mutsuharu Hayashi
Shoichi Maruyama
Seiichi Matsuo
Makoto Nakao
Teruo Tsuchiya
Hitomi Teramachi
Publikationsdatum: 01.12.2015
Verlag: Springer Japan
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 6/2015
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-015-1115-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1